We are bringing together world-class expertise and drug development talent to turn our vision into a reality. We are driven by exceptional science and united in the pursuit of effective therapies for treatment of devastating neurodegenerative diseases.
Chief Financial Officer
DANIEL G. CHAIN, PhD
Dr. Chain is a seasoned biotechnology executive, innovator and scientist entrepreneur who has established and led several biotechnology companies focused on neurodegeneration. He is an inventor of numerous patents and was a pioneer in AD immunotherapy research, initially focused on beta-amyloid lowering strategies. His technology was licensed to Elan/Wyeth and Pfizer. He obtained his PhD in Biochemistry from the Weizmann Institute of Sciences in Israel and was a Howard Hughes post-doctoral research fellow at the Center for Neurobiology and Behavior at Columbia University in New York.
Peter McGowan brings 30 years of international experience in both public and private companies including as CFO of several emerging biotechnology companies, helping them grow and optimize their performance. Peter specializes in ensuring effective finance and administrative functions, raising venture capital and business development. He previously held senior global finance leadership positions at Mundipharma and PPD, a global clinical contract research organization. Peter is a Fellow of the Association of Chartered Certified Accountants.
Richard A. Margolin, MD
Dr. Margolin is a physician-scientist trained in psychiatry and nuclear medicine with extensive academic and pharmaceutical industry experience. He has held positions at Pfizer, CereSpir, Janssen Alzheimer Immunotherapy, Schering-Plough/Merck, and i3 Research. Prior to working in the pharmaceutical industry, Dr. Margolin built and directed the Division of Geriatric Psychiatry at Vanderbilt University and later led the University of Southern California’s Consultation-Liaison Psychiatry Division. He received an AB degree from Harvard College magna cum laude and an MD degree from the University of California, Irvine. He has authored or co-authored 60 scientific publications.
ANDREW J. HEATH, MD, PhD
Chairman
Previously Dr. Heath was CEO of Protherics. He has also held senior positions at Astra AB and Astra USA and at Glaxo Sweden. Dr. Heath currently serves on the boards of Oxford Biomedica Plc and Novacyt SA.
JOHN S. GOGOL
Director
For more than 20 years, Mr. Gogol has assisted individual and institutional clients with identifying business opportunities for investment, merger and acquisition, especially within the pharmaceutical and financial sectors. He is a current Board member of Landmark Fiduciaire (Suisse) SA, and previously served as a director of Antares Pharma Inc.
PARAG SAXENA
Director
Mr. Saxena Managing Partner and CEO of Vedanta Capital and New Silk Route Partners. Previously, he was CEO of INVESCO Private Capital where he personally led more than 90 investments including in Alkermes, Celgene and Genomic Health. Mr. Saxena has provided recommendations on the landscape and regulatory environment for small businesses and venture capital to representatives of the US Congress.
SHAFIQUE VIRANI, MD
Director
Dr. Virani was instrumental in building an industry leading portfolio in neuroscience, ophthalmology and rare diseases at Roche where he held various positions of increasing seniority globally culminating as Global Head of Business Development, Licensing and M&A for neuroscience, ophthalmology and rare diseases. Dr. Virani subsequently served as CEO-in-Residence at BridgeBio Pharma and is currently Chief Business Officer at Recursion. He trained as a neurosurgeon in Cambridge UK and Boston.
